Brokerages predict that Celgene Co. (NASDAQ:CELG) will report earnings of $2.73 per share for the current quarter, according to Zacks. Four analysts have made estimates for Celgene’s earnings, with the highest EPS estimate coming in at $2.93 and the lowest estimate coming in at $2.65. Celgene posted earnings of $2.29 per share during the same quarter last year, which would suggest a positive year over year growth rate of 19.2%. The firm is expected to announce its next earnings results on Thursday, October 24th.
According to Zacks, analysts expect that Celgene will report full-year earnings of $10.91 per share for the current fiscal year, with EPS estimates ranging from $10.67 to $11.37. For the next fiscal year, analysts expect that the business will report earnings of $11.83 per share, with EPS estimates ranging from $9.50 to $13.09. Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that that provide coverage for Celgene.
Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $2.61 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.44 by $0.17. The company had revenue of $4.40 billion for the quarter, compared to analyst estimates of $4.22 billion. Celgene had a net margin of 32.24% and a return on equity of 89.93%. Celgene’s quarterly revenue was up 15.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.16 EPS.
A number of brokerages have recently commented on CELG. Zacks Investment Research raised Celgene from a “sell” rating to a “hold” rating and set a $94.00 price objective on the stock in a report on Tuesday, July 23rd. Mizuho lowered Celgene from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $103.00 to $100.00 in a report on Monday, August 19th. ValuEngine cut Celgene from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 1st. BidaskClub downgraded shares of Celgene from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Cowen reissued a “hold” rating and set a $102.00 target price on shares of Celgene in a research report on Tuesday, July 30th. One analyst has rated the stock with a sell rating, eighteen have issued a hold rating and three have given a buy rating to the company’s stock. Celgene currently has a consensus rating of “Hold” and a consensus price target of $94.60.
A number of institutional investors have recently modified their holdings of the business. Archford Capital Strategies LLC lifted its position in Celgene by 277.8% during the 1st quarter. Archford Capital Strategies LLC now owns 272 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 200 shares in the last quarter. Liberty Wealth Management LLC raised its holdings in Celgene by 212.8% during the 2nd quarter. Liberty Wealth Management LLC now owns 294 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 200 shares during the last quarter. Weaver Consulting Group bought a new stake in shares of Celgene during the first quarter worth approximately $29,000. Alera Investment Advisors LLC raised its stake in shares of Celgene by 109.9% during the first quarter. Alera Investment Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 167 shares during the last quarter. Finally, Mizuho Securities Co. Ltd. acquired a new position in Celgene in the first quarter valued at approximately $31,000. 72.51% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ:CELG traded up $0.76 during trading hours on Wednesday, reaching $98.41. The company’s stock had a trading volume of 2,531,009 shares, compared to its average volume of 7,443,118. The company has a market cap of $68.80 billion, a price-to-earnings ratio of 12.93, a price-to-earnings-growth ratio of 0.45 and a beta of 1.41. Celgene has a one year low of $58.59 and a one year high of $98.97. The business’s 50-day moving average is $94.93 and its 200-day moving average is $93.38. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.44 and a quick ratio of 3.32.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Recommended Story: What is the definition of market timing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.